ZBIO Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclona…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? When biotechnology innovators approach the commercialization cliff, market participants must weigh the clinical promise of a lead asset against the stark realities of surging operating expenses and capital dilution. Zenas BioPharma (NASDAQ:ZBIO) finds itself at this critical juncture, balancing robust Phase 3 trial data and expanding international licensing partnerships against widening net losses and complex […] | ||
 Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves? Zenas BioPharma (NasdaqGS:ZBIO) filed shelf registrations totaling more than US$240 million, according to recent regulatory disclosures. The filings include a broad shelf registration for potential future securities offerings across multiple instruments. A separate portion of the shelf is earmarked for an employee stock ownership plan related offering. The new shelf registrations and ESOP related shelf tell only part of the Zenas BioPharma story for investors to weigh. Our analysis turns up... | ||
 Fortune Brands and 4 More Stocks See Action From Activist Investors 13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. | ||
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says Zenas BioPharma (ZBIO) remains undervalued, as investor concerns over its phase 3 INDIGO trial for o | ||